Akseli Hemminki

Akseli Hemminki worked in University of Alabama at Birmingham in 2000-2002, first as a post doctoral researcher and later as a Research Assistant Professor. Soon after his return to Finland in 2002 he founded his own research group in University of Helsinki, Cancer Gene Therapy Group[http://www.hi.helsinki.fi/cgtg/index.htm Cancer Gene Therapy Group] which he is still leading. In 2007-2013 Hemminki worked as a K. Albin Johansson Research Professor.[http://www.biomedicum.fi/index.php?page=387&lang=1 “Finnish Cancer Institute funded Professorship awarded to Akseli Hemminki (in Finnish)” ], Biomedicum Helsinki webpages. Retrieved October 3, 2016. In 2015 he was appointed as a Jane and Aatos Erkko Professor of Oncology for five years period.[http://www.helsinki.fi/hallinto/kansleri/professorit.html “University of Helsinki Professors (in Finnish)”], University of Helsinki web-pages. Retrieved October 3, 2016. Akseli Hemminki has been selected as an "Outstanding Young Person of the World" by Junior Chamber International in 2006.[http://www.jci.cc/local/jciprograms/srilanka/toyp/previoushonorees “JCI Toyp Honeree List”]{{Dead link|date=September 2019 |bot=InternetArchiveBot |fix-attempted=yes }}, Junior Chamber International web-pages. Retrieved December 22, 2016.

Besides his scientific career Hemminki has worked as a physician in 1998-1999, as a resident in 2003-2007 and as a specialist in oncology since 2007 in HUS (Hospital district of Helsinki and Uusimaa)[http://www.hus.fi/en/about-hus/Pages/default.aspx/ HUS] and Docrates Cancer Center.[https://www.docrates.com/en/professionals/ Docrates Cancer Center Professionals]

Akseli Hemminki’s research focuses on cancer immunotherapy and especially on oncolytic adenoviruses.[http://www.kemianteollisuus.fi/en/views-on-chemistry/chemical-industry/revolutionary-wants-to-help-people/ "Now the man who revolutionized cancer treatment is looking to help people"], Kemianteollisuus webpages, "Views on Chemistry". Retrieved December 22, 2016. The goal of his research group is to create a new oncolytic adenovirus based treatment for cancers with no available curative treatment at the moment.[http://www.projectsmagazine.eu.com/randd_projects/developing_new_treatments_for_cancers "Developing New Treatments for Cancers"] Projects Magazine. Retrieved December 22, 2016.[http://www.hightechfinland.com/direct.aspx?area=htf&prm1=885&prm2=article "Using viruses to help battle cancer"] {{Webarchive|url=https://web.archive.org/web/20170107083916/http://hightechfinland.com/direct.aspx?area=htf&prm1=885&prm2=article |date=2017-01-07 }} HighTech Finland webpages. Retrieved December 22, 2016. The key finding of the group is that oncolytic viruses – besides lyse tumor cells by oncolysis – trigger immune response towards the tumor.{{Cite journal |pmid = 20484030|year = 2010|last1 = Cerullo|first1 = V.|title = Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients|journal = Cancer Research|volume = 70|issue = 11|pages = 4297–309|last2 = Pesonen|first2 = S.|last3 = Diaconu|first3 = I.|last4 = Escutenaire|first4 = S.|last5 = Arstila|first5 = P. T.|last6 = Ugolini|first6 = M.|last7 = Nokisalmi|first7 = P.|last8 = Raki|first8 = M.|last9 = Laasonen|first9 = L.|last10 = Särkioja|first10 = M.|last11 = Rajecki|first11 = M.|last12 = Kangasniemi|first12 = L.|last13 = Guse|first13 = K.|last14 = Helminen|first14 = A.|last15 = Ahtiainen|first15 = L.|last16 = Ristimäki|first16 = A.|last17 = Räisänen-Sokolowski|first17 = A.|last18 = Haavisto|first18 = E.|last19 = Oksanen|first19 = M.|last20 = Karli|first20 = E.|last21 = Karioja-Kallio|first21 = A.|last22 = Holm|first22 = S. L.|last23 = Kouri|first23 = M.|last24 = Joensuu|first24 = T.|last25 = Kanerva|first25 = A.|last26 = Hemminki|first26 = A.|doi = 10.1158/0008-5472.CAN-09-3567|doi-access = free}} Recently, Hemminki’s group has focused on attempting to enable T-cell therapy of solid tumors with oncolytic adenoviruses.{{Cite journal |pmid = 25977260|year = 2015|last1 = Tähtinen|first1 = S.|title = Adenovirus Improves the Efficacy of Adoptive T-cell Therapy by Recruiting Immune Cells to and Promoting Their Activity at the Tumor|journal = Cancer Immunology Research|volume = 3|issue = 8|pages = 915–25|last2 = Grönberg-Vähä-Koskela|first2 = S.|last3 = Lumen|first3 = D.|last4 = Merisalo-Soikkeli|first4 = M.|last5 = Siurala|first5 = M.|last6 = Airaksinen|first6 = A. J.|last7 = Vähä-Koskela|first7 = M.|last8 = Hemminki|first8 = A.|doi = 10.1158/2326-6066.CIR-14-0220-T|doi-access = free}}

To facilitate setting up clinical trials Akseli Hemminki has founded two biotechnology companies: 2008 Oncos Therapeutics (merged with Targovax ASA in 2015[http://www.targovax.com/ Targovax ASA][http://www.targovax.com/news/2015/targovax-and-oncos-therapeutics-join-forces-create-nordic-leader-within-immuno-oncology "Targovax and Oncos Therapeutics join forces to create a Nordic leader within immuno-oncology - PRESS RELEASE"] Retrieved December 22, 2016.) and 2013 TILT Biotherapeutics.[http://tiltbio.com/ TILT Biotherapeutics Ltd][http://www.wave3.com/story/34048991/tilt-biotherapeutics-secures-10-m-106m-for-viral-cancer-t-cell-immunotherapy "TILT Biotherapeutics Secures 10 M ($10.6M) for Viral Cancer T-Cell Immunotherapy"]{{Dead link|date=September 2019 |bot=InternetArchiveBot |fix-attempted=yes }} Wave3 News. Retrieved December 22, 2016.[http://european-biotechnology.com/people/start-up-story.html "Start-up Story. Tilt Biotherapeutics - Express to solid tumours"] {{Webarchive|url=https://web.archive.org/web/20161223102218/http://european-biotechnology.com/people/start-up-story.html |date=2016-12-23 }} European Biotechnology Life Science and Industry Magazine. Retrieved December 22, 2016. Oncos completed the first oncolytic virus trial ever performed in Northern Europe in fall 2013.[https://clinicaltrials.gov/ct2/show/NCT01598129 “ONCOS-102 (previously CGTG-102) for Therapy of Advanced Cancers”] Clinicaltrials.gov. Retrieved October 3, 2016. Over 300 patients have been treated with cancer drugs developed by Hemminki.[http://www.asgct.org/members/asgct_news/summer11/index.php?pagecontent=page2&sessioncontent=4 "ASGCT News, Summer 2011. Cancer Gene & Cell Therapy, Symposium 444"] {{Webarchive|url=https://web.archive.org/web/20170217064459/http://www.asgct.org/members/asgct_news/summer11/index.php?pagecontent=page2&sessioncontent=4 |date=2017-02-17 }}. Retrieved December 22, 2016.{{Cite journal |pmc = 4801451|year = 2015|last1 = Hemminki|first1 = O.|title = A century of oncolysis evolves into oncolytic immunotherapy|journal = Oncoimmunology|volume = 5|issue = 2|pages = e1074377|last2 = Hemminki|first2 = A.|pmid = 27057442|doi = 10.1080/2162402X.2015.1074377}}{{Cite journal |pmc = 3914551|year = 2014|last1 = Hemminki|first1 = A.|title = Oncolytic Immunotherapy: Where Are We Clinically?|journal = Scientifica|volume = 2014|pages = 1–7|pmid = 24551478|doi = 10.1155/2014/862925 | doi-access=free }}{{Cite journal |pmc = 4791966|year = 2016|last1 = Ranki|first1 = T.|title = Phase I study with ONCOS-102 for the treatment of solid tumors – an evaluation of clinical response and exploratory analyses of immune markers|journal = Journal for Immunotherapy of Cancer|volume = 4|pages = 17|last2 = Pesonen|first2 = S.|last3 = Hemminki|first3 = A.|last4 = Partanen|first4 = K.|last5 = Kairemo|first5 = K.|last6 = Alanko|first6 = T.|last7 = Lundin|first7 = J.|last8 = Linder|first8 = N.|last9 = Turkki|first9 = R.|last10 = Ristimäki|first10 = A.|last11 = Jäger|first11 = E.|last12 = Karbach|first12 = J.|last13 = Wahle|first13 = C.|last14 = Kankainen|first14 = M.|last15 = Backman|first15 = C.|last16 = von Euler|first16 = M.|last17 = Haavisto|first17 = E.|last18 = Hakonen|first18 = T.|last19 = Heiskanen|first19 = R.|last20 = Jaderberg|first20 = M.|last21 = Juhila|first21 = J.|last22 = Priha|first22 = P.|last23 = Suoranta|first23 = L.|last24 = Vassilev|first24 = L.|last25 = Vuolanto|first25 = A.|last26 = Joensuu|first26 = T.|pmid = 26981247|doi = 10.1186/s40425-016-0121-5 | doi-access=free }}

{{Scholia|author}}

{{Reflist|30em}}

{{Authority control}}

{{DEFAULTSORT:Hemminki, Akseli}}

Category:Finnish oncologists

Category:Living people

Category:1973 births